Home › Compare › FLLHF vs ABBV
FLLHF yields 363.64% · ABBV yields 3.06%● Live data
📍 FLLHF pulled ahead of the other in Year 1
Combined, FLLHF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FLLHF + ABBV for your $10,000?
Fullshare Holdings Limited, an investment holding company, engages in the property development, sale of gear products, and property investment activities in the People's Republic of China, the United States, Europe, Australia, and internationally. It operates through five segments: Properties; Tourism; Investment and Financial Services; Healthcare, Education, and Others; and New Energy. The company develops and sells properties, including residential, commercial, hotels, offices, apartments, and shopping malls; and provides construction related services. It also holds and invests in various investments and financial products, such as listed and unlisted securities, bonds, funds, derivatives, structured, and other treasury products; offers investment and financial related consulting services; and operates hotels, as well as sells tourist goods and provides related services. In addition, the company engages in the manufacture, distribution, and sale of mechanical transmission equipment; and manufacture and sale of gear products. Further, it provides healthcare and education products and related services; and green building services comprising technical design and consulting, green management, and construction services. The company was formerly known as Warderly International Holdings Limited and changed its name to Fullshare Holdings Limited in October 2014. The company was founded in 2002 and is headquartered in Admiralty, Hong Kong.
Full FLLHF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.